Targeted gene repair or targeted gene alteration is a molecular strategy that aims to correct single base mutations responsible for genetic diseases. The concept involves using singlestranded DNA oligonucleotides to direct a nucleotide exchange reaction at the genomic site of the mutation. Investigators have made significant progress in elucidating the mechanism(s) by which the mutation is corrected and have begun to focus on several viable targets that show great potential for clinical application. During the past several years, the field has witnessed a phase transition as the focus has switched from purely basic science to a sustained translational mode. We highlight the important advances over the last two to three years, some of which have moved the technology closer to the clinic while some others have introduced new reasons for caution.
Introduction
In the early 1990s, our laboratory fused a number of previously related observations regarding the capacity of oligonucleotides to direct single base changes in genomic DNA into a novel approach for the treatment of genetic diseases (see Parekh-Olmedo et al. 1 for review). This resulted in the emergence of a strategy for repairing single base mutations in human cells. Early on, the concept centered around the idea that DNA oligonucleotides (ODNs) could localize to the target site within a chromosome and hybridize to a complementary DNA sequence. If the ODN contained one base that could not base pair with the target sequence properly, a mismatch would be created; such a distortion in the helix would be recognized by enzymes that catalyze nucleotide exchange events. The mismatch would then be eliminated by the insertion of a proper complementary base and the continuity of the helix would be restored. In principle, all of the biochemical and molecular pathways required for nucleotide exchange are known to exist. These include DNA pairing, alignment in homologous register, base excision and base insertion. The reaction depends on the composite activity of these enzymes induced by the successful pairing of the ODN with the target strand of the helix. While there have been important extensions and modifications of this model, the underlying concept has remained by and large intact.
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Prospects
Application of targeted gene alteration (TGA) to several viable target diseases should mature based on newly developed delivery strategies Developmental and clinical strategies must be established to attain and sustain significant correction levels in primary cells Translational work from cell-based assays to primary cells or animal models is underway and, as a result, more clinical targets will be identified with a greater degree of confidence Greater focus on how cells within in vivo models respond to the introduction of the oligonucleotides will enable more universal applications of TGA Muscle, liver and eye appear to be viable clinical targets for TGA Here, we focus on (1) advances in the understanding of the mechanism of gene repair; (2) appreciation of the cellular response to the process of gene repair and (3) developments toward clinically relevant targets.
A consensus terminology emerges: targeted gene alteration
Papers published over the last three years reveal that the process of gene repair has appeared under a number of new names, some descriptive and some operational; Table 1 presents a partial list of these titles. During the early phases of our work, we recognized that ODNs could be used to either induce or repair single-nucleotide mutations so, terms including 'gene alteration', 'gene modification' or even 'mutagenesis' actually serve to emphasize a more universal application of the ODN. We now suggest that at least some consensus should be reached and consistent, broad terminology should be adopted. We suggest 'Targeted Gene Alteration' (TGA) as a unifying title. While, in most cases, the intent of a clinically relevant experiment is to repair the genetic mutation and restore the expression of the functional protein, it is plausible to induce or modify expression levels using this technique. Thus, the terminology surrounding the technique should reflect this potential approach.
DNA replication plays a crucial role in TGA
Several mechanistic models of gene repair (TGA) were presented in the review by Parekh-Olmedo et al.
1
These included pathways that incorporated DNA replication into the gene repair (TGA) process. At a minimum, it is now clear that replication serves to destabilize nucleosome structure thereby increasing target site accessibility. It was proposed that the ODN becomes incorporated into the nascent replicated strand at or near the fork, thus passing directly into the helix after binding to the target site. This idea gains strong support from numerous studies that identify S phase of the cell cycle as the time at which the TGA process occurs most readily (see below).
Krauss and colleagues 12 used ODNs bearing octyl or other blocking groups at either the 3 0 end, or both 3 0 and 5 0 ends, to ask whether DNA replication plays a role in TGA. End-modification resulted in a severe reduction in TGA activity. These authors tested alternative end blocking groups and observed the same reduction in activity. Since they demonstrated that all modified ODNs tested entered the cell with the same efficiency, the decrease in repair is likely to be a direct result of the ends being chemically blocked. These results support strongly the hypothesis that incorporation of the targeting ODN into the replicating helix followed by natural extension is a basic feature of the TGA reaction. Olsen et al. 15 linked DNA synthesis and TGA by describing the results of experiments in which correction activity was blocked by the presence of replication inhibitors. Under these conditions, TGA frequencies were dramatically reduced, results that mirror the observations of Brachman et al. 16 and Engstrom et al.
17
In another study, Radecke et al. 18 provided more data in support of the replication model. This work was carried out as a series of experiments designed to capture the ODN after catalysis of a TGA event. They used a biotinlabeled targeting ODN and isolated genomic DNA fragments, which had become attached (ligated) during the TGA reaction, from corrected cells. They proposed that during TGA, the ODN becomes incorporated into the helix as a 'pseudo-Okasaki fragment' and provides a functional 3 0 -OH group for replicative extension. Several groups have also suggested that the lagging strand may be more amenable to incorporation of the ODN than the leading strand (see Parekh-Olmedo et al.
1 for review). Preferential activity within the lagging strand may explain the 'transcriptional strand bias' often reported in TGA reactions since the polarity of DNA replication through the target site is often unknown.
The hypothesis that DNA synthesis is the major factor in regulating repair frequencies in TGA has been strengthened further by results obtained in Escherichia. coli. Huen and et al. 3 reported that replication enhanced 'single-stranded oligonucleotide -mediated mutagenesis', a reaction in which ODNs are annealed to the target site through the action of the l phage protein, Recb; the use of Recb in recombineering had been reported previously by Court and colleagues. 19 Huen et al.
2 exploited this approach by targeting antibiotic resistant reporter genes and gained important data that supported the annealing integration model. Clearly, the model proposed by Parekh-Olmedo et al.
1 relies heavily on the recombineering work in E. coli. In the last several years, the overwhelming amount of data generated from studies aimed at elucidating mechanisms, align with the concept that DNA replication activity is at the heat of the TGA reaction.
While DNA synthesis seems to regulate TGA, there is still a potential role for transcriptional activity in promoting the reaction. Yoon and colleagues 20 propose that TGA occurs via an excision repair event during transcription, in which nucleases remove 23-28 bases of the template DNA in response to the targeting ODN. One might envision this occurring if the target gene is transcriptionally active and the nucleosomal structure is dynamic, thereby increasing accessibility of the site. Single-stranded oligonucleotide gene targeting Murphy et al.
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There are, however, several experimental observations that are not consistent with this mechanism. Some of these problems were best characterized by Olsen et al. 12 First, as reported by many labs, 17, 21, 22 little correction activity occurs in the G1 phase of the cell cycle. Second, it is now clear that proteins involved in homologous recombination participate in TGA because transcription itself enhances homologous recombination. The role of transcription may be best characterized as ancillary or supplemental to that of replication in promoting TGA in dividing cells. 2 A unique role for the mismatch repair pathway in TGA
The final advancement in the area of TGA mechanism has centered on the role of mismatch repair (MMR) proteins. When mouse embryonic stem cells are targeted using ODNs, an increase in TGA frequency is observed as the expression of proteins involved in the MMR pathway is suppressed. 23 In support of this observation, several labs have demonstrated that transient knockdown of MMR protein, MSH2, elevated nucleotide substitution but with various efficiencies. Their work suggested that a type of targeted base hierarchy existed and was affected, at least in part, by concurrent suppression (or absence) of multiple proteins involved in MMR. Dekker et al. 24 subsequently demonstrated that mouse embryonic stem cells were more amenable to gene disruption when the cell was devoid of MSH2. Maguire and Kmiec recently showed that MSH2 suppresses TGA in mouse embryonic fibroblasts by experiments carried out in cells lacking MSH2 or by knocking down MSH2 in wild-type mouse embryonic fibroblasts using RNAi. 25 These data lend support to previous work in yeast, in which strains lacking PMS1 or PMS2 enabled a higher level of TGA directed by ODNs. Taken together, these observations provide an interesting twist on the replication-annealing-incorporation model. Since MMR proteins are known to suppress the integration of exogenous foreign DNA into a host genome, their absence may remove a block that limits the ODN's integration process within a replicative event at the target site. While it is fair to say that much more work is required to elucidate a mechanism, the relationship between replication processes (coupled perhaps to MMR activity) and TGA has been strengthened significantly over the past three years.
Progress toward appreciating the cell's response to TGA has been made It was established several years ago that the introduction of single-stranded DNA into mammalian cells induces a DNA damage response with the concurrent activation of apoptotic signals. One might imagine that the abundance of free ends provided by the ODNs is perceived by the cells as chromosomal breakage or damage. An efficient and rapid molecular response is therefore, quite predictable. To this end, Olsen et al. 15 first reported unique behavior in corrected cells. Cells appear to stall in G2 or at G2/M border after the TGA reaction is completed. The most important characteristic observed by Olsen et al. 15 was the effect of TGA on cell cycle progression through S phase. Brachman and Kmiec 16 described this phenomenon earlier as an elongation of S phase and proposed that the introduction of ODNs actually elevated TGA activity by its inherent action of lengthening S phase where TGA most readily occurred (see above). Since, elongation of S phase takes place through the activation of Checkpoint Proteins 1 and 2 (Chk1 and Chk2) 21, 26 (Chk1 also is activated in response to singlestranded DNA), these proteins should be activated and detectable during the TGA reaction. Ferrara et al. 21 found that these proteins were,in fact, activated not only in the TGA reaction but also specifically in corrected cells. These observations raised concerns about the use of TGA as a therapeutic regime because corrected cells appeared to have reduced replication and cell division capability. This issue was examined in greater detail however, and it was found that corrected cells regain replicative activity fully. 22 During this lag period, the non-corrected cells advance through several rounds of replication and cell divisions initially 'outgrowing' the corrected population. As a result the correction frequency appears to diminish until the replication potential of corrected cells is restored. Surprisingly, this phenomenon is not observed in animal models wherein correction levels have been reported to remain constant and stable for 3-6 months after ODN administration. 27 Finally, a correlation between TGA and cells stalled in S phase was reported by Wu et al. 28 These authors found that cells treated with thymidine to induce cell cycle synchrony also exhibited elevated levels of TGA. They concluded that (1) the frequency of TGA was increased due to a 'thymidine-induced slowdown of replication fork progression'; and (2) this phenomenon was unique to the use of thymidine as the synchronization reagent. Recent results support the first conclusion, but not the second. Both Olsen et al. 15 and Engstrom and Kmiec 17 found that multiple reagents that induce retardation of fork progression stimulate TGA, consistent with the earlier observations that demonstrated the value of replicating cells to higher levels of TGA. Taken together, the consensus view is that introduction of ODNs into mammalian cells affects the cells by initially slowing DNA replication activity in a transient fashion, thereby providing a more amenable environment for TGA to take place.
Neuromuscular and retinal degeneration diseases emerge as promising clinical targets
The translation of TGA from basic science to therapeutic application has been steady and exciting to watch. 27 continued their work with chimeric RNA/DNA ODNs oligonucleotides that correct the dystrophin gene mutation at the genomic level both in vitro and in vivo. Chimeric RNA/DNA ODNs (chimeraplasty) and singlestranded ODNs were able to correct the dystrophin mutations in vitro and in vivo and the corrected cells maintained their levels of correction for three months in vivo. In these studies, the non-transcribed strand was (manuscript-submitted) in studies where the production of wild-type dystrophin was generated by TGA in myoblasts isolated from mdx 5cv mice. While, it is clear that more developmental work is needed, the potential for TGA as a treatment for Duchenne's muscular dystrophy remains quite strong.
During the past several years, significant studies have been carried out in the development of molecular medicine approaches for retinal disease. In one case, cells of the neural retina have been identified as a target for TGA. The eye is a particularly attractive target because therapeutic effects that impact the degree of blindness could be obtained with modest levels of repair. Ciavatta et al.
14 used an experimental strategy in which cell-free extracts were produced from target tissue and TGA levels were measured by biochemical and genetic readout. These workers clearly established that murine retinal nuclei have the capacity to support significant levels of TGA and used the chimeric RNA/DNA ODN to direct base changes.
Andrieu-Soler et al. 29 extended TGA from retinal cell extracts to an in vivo model system. The aim of this study was to correct a point mutation in the b-PDE (b-subunit of rod photoreceptor cGMP-phosphodiesterase) gene in mouse retinas. This mutation causes rod photoreceptor loss in mice and similar mutations in the human gene led to retinal degeneration. The experimental strategy involved delivering a 25-mer using iontophoresis and intravitreal injection into C3H/henJ (rd1) mouse retinas with the aim of correcting the rd1 mutation. TGA at this site would lead to the appearance of b-PDE and preservation of rhodopsin in cells of the outer nuclear layer and result in increased photoreceptor counts. These authors reported successful application of TGA in rd1 retinas evidenced by both genotypic and phenotypic conversions. They stated that a 'significant rescue of photoreceptors was observed', perhaps because the mode of delivering ODNs to the target tissue had been optimized. TGA for retinal diseases is a particularly attractive target since degeneration often progresses slowly, enabling an opportunity for repeated administration through optimized ODN delivery mechanisms. Thus, over the course of the last three years, muscle cells and retinal cells appear to have emerged as the most viable targets for the translation of TGA into the clinical setting.
Prospects for the future
The field of gene repair (TGA) has begun to mature and two areas seem to be generating the most interest, each with advantages and disadvantages especially with regard to realistic clinical development. The first is muscular dystrophy which may simply act as a platform for other neuromuscular disorders such as spinal muscular atrophy. Selective muscle groups can be targeted by direct injection, aided perhaps by electromagnetic stimulation, providing a physical mode of delivery directly to the target tissue. Alternatively, myoblasts can be treated ex vivo, differentiated and transplanted back into the patient. Thus, a method for delivering the ODN to where it needs to be in order to direct correction is already under development. But, dystrophin is not transcriptionally active in myoblasts and the degree of correction needed to elicit a clinically relevant response is unknown. Furthermore, dystrophin is a non-secreted, structural protein so that many nuclei will have to be corrected within myoblasts to produce enough wild-type protein even to detect, let alone become beneficial. A strong case can be made however for muscular dystrophy as a serious target TGA: simply stated, it works in a reproducible and robust manner. 29 Another promising target for TGA is the eye. Recently, a flurry of activity in the biotechnology community has taken place surrounding the use of synthetic nucleic acids such as DNA aptamers and RNAi for clinical applications. Parallel studies, cited above, place TGA as a viable option for those seeking a permanent correction. Delivery mechanisms of large molecules to the eye continue to improve, enabling the transport of enough ODN to the target cells to illicit a positive response. More importantly, retardation of even a modest amount of retinal degeneration would provide significant clinical benefit. Multiple rounds of TGA might eventually enable a stable, permanent repair of a retinal mutation with a cessation of treatment as the clinical goal. This nontransient characteristic of TGA strategy has always been among its most attractive attributes.
The translation of TGA into the clinical setting has several unique barriers, some scientific, some not. One of the most important publications over the last two years outlined the work of Murphy et al. 5 While these investigators have been laboring to enable TGA for embryonic stem cells, they took a fundamentally reductionist approach to the problem of low ESC gene modification. It has been well established (see citations above) that transporting the ODN to the nucleus is a fundamental requirement for TGA. Toward this end, they found that correction efficiencies varied with lipofection reagents. They also found variance in the clonal lines they established even when using the same ODN to promote the correction event, an observation previously reported by Hu et al. 30 Finally, they observed a hierarchy of correction levels based on various mismatched bases suggesting that the repair machinery, affected perhaps by the process of DNA replication, acts differently on various mismatches. These and other scientific studies have established fundamental and scientific explanations for the initial variation observed with this technique. Ciavatta et al.
14 also showed that the degree of gene repair directed by the chimeric RNA/ DNA oligonucleotide is related to the degree of chimera degradation, again providing a scientific explanation for the lack of robustness seen in some original reports.
Can targeted gene alteration translate to the clinical setting?
As the field has begun to focus on questions regarding how it works rather than if it works, some interesting caveats have come forward that have an impact on Targeted gene alteration H Parekh-Olmedo and EB Kmiec clinical development. As described above, it is now clear that DNA replication plays an important role in achieving significant levels of TGA. Lengthening S phase to increase target accessibility has proven to be the most significant stimulant of TGA frequency. Yet, this certainly will be a vexing problem for translation into humans. Many potential target tissues in vivo are not undergoing high levels of DNA replication or cell division. Thus, while mechanistic studies have been helpful in identifying elements and processes that regulate TGA, the results of these studies present an interesting problem. How do we stimulate metabolic activity in target tissue so that significant amounts of nucleotide exchange can take place? There are several ways to approach this problem. First, it is encouraging that transcriptional activity has been shown to enhance TGA, regardless of the degree. 20 One might take advantage of this pathway by treating animals or patients with reagents that upregulate transcriptional activity such as inhibitors of histone deacetylases. An overall elevation in the gene expression may promote dynamic chromatin structural changes that increase accessibility to the target site. Second, the utilization of delivery strategies that induce modest levels of tissue damage requiring wound healing. Such responses would activate DNA replication and cell division processes. For example, one might even imagine partial liver resection as combinatorial therapy with TGA directed against genetic diseases treatable in liver. Finally, perhaps a more intense focus on ex vivo therapy wherein primary cells are removed, transfected and then allowed to expand in culture through replication and cell division in the presence of the ODN. Subsequent transplantation of expanded cell cultures might produce positive clinical outcomes. This might be applicable to situations wherein differentiation does not ultimately defeat the purpose of targeting progenitor cells. The plethora of genetic diseases for which there is only unreliable therapy available, focuses the development of TGA and related therapies as a worthy endeavor.
